Rafferty Asset Management’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-352,695
Closed -$5.19M 1186
2024
Q1
$5.19M Buy
352,695
+257,963
+272% +$3.9M 0.02% 470
2023
Q4
$911K Buy
+94,732
New +$655K ﹤0.01% 841
2022
Q2
Sell
-207,643
Closed -$1.83M 1190
2022
Q1
$1.83M Buy
207,643
+35,864
+21% +$396K 0.01% 633
2021
Q4
$2.76M Buy
171,779
+67,848
+65% +$1.28M 0.01% 556
2021
Q3
$2.18M Sell
103,931
-18,360
-15% -$442K 0.01% 618
2021
Q2
$3.29M Buy
122,291
+11,922
+11% +$349K 0.02% 482
2021
Q1
$3.52M Buy
110,369
+87,893
+391% +$2.13M 0.02% 390
2020
Q4
$514K Sell
22,476
-29,933
-57% -$689K 0.01% 680
2020
Q3
$1.32M Buy
52,409
+42,294
+418% +$1.15M 0.02% 531
2020
Q2
$282K Buy
+10,115
New +$176K ﹤0.01% 843
2020
Q1
Sell
-49,956
Closed -$544K 732
2019
Q4
$544K Sell
49,956
-43,335
-46% -$429K 0.01% 676
2019
Q3
$1.19M Sell
93,291
-49,627
-35% -$715K 0.02% 502
2019
Q2
$2.42M Buy
142,918
+93,157
+187% +$1.6M 0.04% 310
2019
Q1
$895K Buy
+49,761
New +$860K 0.01% 573

Other funds holding MGNX

Rafferty Asset Management's MGNX Position: Q2 2024 in Review

Rafferty Asset Management sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 352,695 shares — an estimated $5.19M sold.

Rafferty Asset Management first reported a position in MGNX in Q1 2019 and held it in 14 quarters. The position peaked at $5.19M in Q1 2024. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

  • Rafferty Asset Management reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 352,695 MacroGenics shares in Q2 2024, an estimated $5.19M.
  • Rafferty Asset Management first reported a position in MacroGenics in Q1 2019 and held it in 14 quarters.
  • Rafferty Asset Management's MacroGenics position peaked at $5.19M in Q1 2024.
  • 146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Rafferty Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.